medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 6

<< Back Next >>

Med Int Mex 2023; 39 (6)

Association between D-dimer levels and mortality in patients with pneumonia due to SARS-CoV-2

May HPR, Olán F, Hernández NË, Rojas GJS, Morales CJA, Baños GMA

Language: Spanish
References: 16
Page: 864-872
PDF size: 218.31 Kb.


ABSTRACT

Objective: To assess whether D-dimer measured in the first 24 hours of hospital admission is a prognostic predictor of mortality in patients with moderate to severe pneumonia secondary to infection with the SARS-CoV-2 virus.
Materials and Methods: An observational, cross-sectional, and analytical study was carried out from July 2020 to July 2021 on hospitalized patients with a diagnosis of SARS-CoV-2 pneumonia and who had D-dimer measurements at hospital admission. We evaluated D-dimer levels and gave follow-up until the type of outcome.
Results: We evaluated 251 patients diagnosed with SARS-CoV-2 infection; 60% of the patients were male. The most frequent comorbidities were diabetes and arterial hypertension. The hospital mortality of these patients was 42%. In addition, mechanical ventilation and elevated D-dimer levels were predictors of mortality, regardless of the patient’s comorbidities.
Conclusions: Elevated levels of D-dimer, taken in the first 24 hours of hospital admission, can significantly predict a worse clinical outcome and mortality.


REFERENCES

  1. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context:D-dimer. J Am Coll Cardiol 2017; 70 (19): 2411-2420. Doi:10.1016/j.jacc.2017.09.024.

  2. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, et al.Incidence of thrombotic complications in critically ill ICUpatients with COVID-19. Thromb Res 2020; 191: 145-147.Doi: 10.1016/j.thromres.2020.04.013.

  3. Yao Y, Cao J, Wang Q, Shi W, et al. D-dimer as a biomarkerfor disease severity and mortality in COVID-19 patients:a case control study. J Intensive Care. 2020;8:49. Doi:10.1186/s40560-020-00466-z.

  4. Chen T, Wu D, Chen H, Yan W, et al. Clinical characteristicsof 113 deceased patients with coronavirus disease 2019:retrospective study [published correction appears in BMJ.2020; 368: m1295]. BMJ 2020; 368: m1091. Doi: 10.1136/bmj.m1091.

  5. Vidali S, Morosetti D, Cossu E, Luisi ML, et al. D-dimer asan indicator of prognosis in SARS-CoV-2 infection: a systematicreview. ERJ Open Res 2020; 6 (2): 00260-2020. Doi:10.1183/23120541.00260-2020

  6. Cortes-Telles A, Gutiérrez-Solis AL, Álvarez-Sánchez VA,González-Garay AG, Lugo R, Avila-Nava A. Dynamic inflammatoryresponse among routine laboratory biomarkers andtheir predictive ability for mortality in patients with severeCOVID-19. Front Med (Lausanne) 2022; 9: 1047304. Doi:10.3389/fmed.2022.1047304.

  7. Altuve-Quiroz J, Fernández-Reynoso C, Mondragón-SotoMG, Juárez-Ramírez JI. The role of biochemical and respiratorymarkers in the mortality of patients with SARS-CoV-2infection in a Mexican population. Cureus 2022; 14 (6):e26249. Doi: 10.7759/cureus.26249.

  8. Romero-Gameros CA, Vargas-Ortega G, Rendón-MaciasME, Cuevas-García CF, et al. Risk factors associatedwith mortality among patients with COVID-19: Analysisof a cohort of 1213 patients in a tertiary healthcarecenter. J Clin Med 2022; 11 (10): 2780. Doi: 10.3390/jcm11102780.

  9. Martínez-Guerra BA, Medrano-Borromeo C, González-Lara MF, Román-Montes CM, et al. Predictors ofpoor outcomes in young non-comorbid patients withCOVID-19. Rev Invest Clin 2022; 74 (5): 268-275. Doi:

  10. 10.24875/RIC.22000162.10. Ordinola-Navarro A, Cobos-Quevedo OJ, Cervantes-BojalilJ, Perez-Alvarez E, et al. High mortality at the beginning ofthe COVID-19 pandemic in a referral center in the metropolitanarea of Mexico City. J Infect Dev Ctries 2022; 16 (8):1269-1277. Doi: 10.3855/jidc.14389.

  11. Ramírez-Plascencia LE, Vázquez-León AP, Villaseñor-MagañaA, Correa-Valdéz M, Carrillo-Ibarra S, Sifuentes-FrancoS. factors possibly associated with mortality in intubatedCOVID-19 patients: A retrospective study. Pathogens 2022;11 (2): 235. Doi: 10.3390/pathogens11020235.

  12. Guan WJ, Ni ZY, Hu Y, Liang W, et al. Clinical characteristicsof coronavirus disease 2019 in China. N Engl J Med 2020;382 (18): 1708-1720. Doi: 10.1056/NEJMoa2002032.

  13. Zhang JJ, Dong X, Cao YY, Yuan Y, et al. Clinical characteristicsof 140 patients infected with SARS-CoV-2 in Wuhan,China. Allergy. 2020; 75 (7): 1730-1741. Doi: 10.1111/all.14238.

  14. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulanttreatment is associated with decreased mortality in severecoronavirus disease 2019 patients with coagulopathy. JThromb Haemost 2020; 18 (5): 1094-1099. Doi: 10.1111/jth.14817.

  15. Barouch DH. Covid-19 vaccines - immunity, variants,boosters. N Engl J Med 2022; 387 (11): 1011-1020. Doi:10.1056/NEJMra2206573.

  16. Zhou F, Yu T, Du R, Fan G, et al. Clinical course and riskfactors for mortality of adult inpatients with COVID-19in Wuhan, China: a retrospective cohort study Lancet2020; 395 (10229): 1054-1062. Doi: 10.1016/S0140-6736(20)30566-3.




2020     |     www.medigraphic.com